Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

Executive Summary

Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.

Advertisement

Related Content

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
Strong Sobi With New Asset: A Takeover Target For Sanofi?
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Takeda, Shire Finally Seal £46bn Deal
Teva Pushes CGRP Timeline Back To End Of 2018
Mum On Takeda, Shire Outlines Two-Division Performance

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123486

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel